From Wikipedia, the free encyclopedia
Jump to: navigation, search
AM-630 structure.png
Legal status
Legal status
CAS Number
PubChem CID
ECHA InfoCard 100.229.964
Chemical and physical data
Formula C23H25IN2O3
Molar mass 504.360 g/mol
3D model (JSmol)
 NYesY (what is this?)  (verify)

AM-630 (6-Iodopravadoline) is a drug that acts as a potent and selective inverse agonist for the cannabinoid receptor CB2, with a Ki of 32.1 nM at CB2 and 165x selectivity over CB1, at which it acted as a weak partial agonist.[1][2] It is used in the study of CB2 mediated responses and has been used to investigate the possible role of CB2 receptors in the brain.[3][4] AM-630 is significant as one of the first indole derived cannabinoid ligands substituted on the 6-position of the indole ring, a position that has subsequently been found to be important in determining affinity and efficacy at both the CB1 and CB2 receptors, and has led to the development of a large number of related derivatives.[5][6][7][8][9]

See also[edit]


  1. ^ Ross RA; et al. (February 1999). "Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630". British Journal of Pharmacology. 126 (3): 665–72. PMC 1565857Freely accessible. PMID 10188977. doi:10.1038/sj.bjp.0702351. 
  2. ^ Murataeva, N.; MacKie, K.; Straiker, A. (2012). "The CB2-preferring agonist JWH015 also potently and efficaciously activates CB1 in autaptic hippocampal neurons". Pharmacological Research. 66 (5): 437–42. PMC 3601544Freely accessible. PMID 22921769. doi:10.1016/j.phrs.2012.08.002. 
  3. ^ Morgan NH, Stanford IM, Woodhall GL (September 2009). "Functional CB2 type cannabinoid receptors at CNS synapses". Neuropharmacology. 57 (4): 356–68. PMID 19616018. doi:10.1016/j.neuropharm.2009.07.017. 
  4. ^ Ishiguro H; et al. (May 2010). "Brain cannabinoid CB2 receptor in schizophrenia". Biological Psychiatry. 67 (10): 974–82. PMID 19931854. doi:10.1016/j.biopsych.2009.09.024. 
  5. ^ Eissenstat, M. A..; et al. (1995). "Aminoalkylindoles: Structure-Activity Relationships of Novel Cannabinoid Mimetics". Journal of Medicinal Chemistry. 38 (16): 3094–105. PMID 7636873. doi:10.1021/jm00016a013. 
  6. ^ Hongfeng Deng. Design and synthesis of selective cannabinoid receptor ligands: Aminoalkylindole and other heterocyclic analogs. PhD Dissertation, University of Connecticut, 2000.
  7. ^ Hynes J; et al. (September 2002). "C-3 Amido-indole cannabinoid receptor modulators". Bioorganic & Medicinal Chemistry Letters. 12 (17): 2399–402. PMID 12161142. doi:10.1016/S0960-894X(02)00466-3. 
  8. ^ Frost, J. M.; et al. (2008). "Indol-3-yl-tetramethylcyclopropyl Ketones: Effects of Indole Ring Substitution on CB2 Cannabinoid Receptor Activity". Journal of Medicinal Chemistry. 51 (6): 1904–12. PMID 18311894. doi:10.1021/jm7011613. 
  9. ^ Adam, J. M.; et al. (2010). "Design, synthesis, and structure–activity relationships of indole-3-carboxamides as novel water soluble cannabinoid CB1 receptor agonists". MedChemComm. Royal Society of Chemistry. 1: 54. doi:10.1039/c0md00022a.